PBTC-N11: Immunologic Profiles of Patients with Newly Diagnosed Medulloblastoma at Initial Diagnosis and During Standard Radiation and Chemotherapy.

Why are we doing this research?

This research study is studying biomarkers in blood samples from young patients with newly diagnosed brain tumors undergoing standard radiation therapy and chemotherapy

Who can participate?

Patients between the ages of 4 and 21 who meet the following criteria can participate in this study:

DISEASE CHARACTERISTICS (meets one of the following criteria):


  • Histologically confirmed posterior fossa tumor
  • Newly diagnosed disease
  • Medulloblastoma OR non-medulloblastoma (pilocytic astrocytoma, ependymoma, atypical rhabdoid tumor, or others)
  • Scheduled to undergo craniotomy and tumor resection
  • Chiari malformation
    • Requires craniectomy for decompression
      • No secondary decompression




  • No unexplained febrile illness
  • No active infection
  • No autoimmune disorders such as inflammatory bowel disease, juvenile rheumatoid arthritis, or systemic lupus erythematosus
  • No other immunosuppressive disorders (e.g., HIV infection)




  • See Disease Characteristics



  • From 4 to 21 years old


  • Cancer - Brain and Spinal Tumors


  • Female
  • Male

What will happen in the study?

Patients with Chiari malformation and patients with posterior fossa tumor undergo standard surgery. Patients with posterior fossa tumor also receive standard radiotherapy and chemotherapy.

Blood samples are collected at baseline and periodically to measure the level of circulating T-regulatory cells.


For more information contact:

Cincinnati Children’s Hospital Medical Center
Division of Hematology/Oncology
3333 Burnet Ave., Cincinnati, OH 45229-3039
Phone: 513-636-2799